European Journal of Biomedical and Pharmaceutical Sciences

PHARMACOTHERAPEUTIC EVALUATION OF COVID-19 PATIENTS WITH CO-MORBIDITIES

Mohammed Ashfaq Hussain*, Syeda Juweria Taruj, Md Fayaz Khan J., Lubna Muzaffar Hussain, Koganti Sai Siri and Anupama Koneru

ABSTRACT

Treatment approach for COVID-19 is complicated by many factors, evaluating the effectiveness of drug therapy is crucial to improve health related quality of life of COVID-19 patients. Elderly people and People with multiple disease states are more likely to suffer with severe COVID-19 infection hence, appropriate treatment approach for such vulnerable patients is required. The main objective of the study is to determine therapeutic appropriateness with respect to age and disease state of the patients. A prospective observational cohort study was conducted in a tertiary care hospital for duration of 6 months involving 184 COVID-19 affected patients with various co- morbidities. The study re-evaluates the drug therapy and assesses the quality of life of recovered COVID-19 patients by providing them with a questionnaire to fill, and following up with them for 1-2 months from the time of recovery for proper assessment of the questionnaire. The questionnaire is designed in such a manner that it is easy to answer and evaluates the patient in various physical, mental and social domains. Statistical analysis i.e. t test was carried out on inflammatory biomarkers values obtained before and after treatment to assess improvement in COVID patients. Primary outcomes were re-evaluating the drug therapy, quality of life assessment of patients recovered from COVID-19, survival rate and mortality rate. Secondary outcomes were focused on drug-drug interactions, adverse effects, need of mechanical ventilation, estimation of ICU stay and hospital stay, association between co-morbidities and COVID-19, evaluating laboratory findings and association of complications with age and co-morbidities.

Keywords: COVID-19, co-morbidities, Quality of life, Therapeutic appropriateness, Complications, Mortality rate.